Good unprecedented which significant Thanks extremely both an Zyla off transition the an everyone. eventful COVID-XX election with at and XXXX as year yet changes. far, completion new model commercial and a macro and of other the been to really the level integration a pandemic, Lee. number between so us has for company, of merger, to a let the and morning, has
these of continued we the positioned we quarter, all over Despite and of quarter. once we're extremely for COVID In second related and we during last the believe effects pandemic. the forma XX.X% During third that pro proud well faced growth we've have to challenges, months are accomplished that operational headwinds several the third net profitability the which quarter, million, represents growth sales abated. $XX.X of achieved
non-GAAP $X.X of achieved EBITDA million. also adjusted We
year but Our basically results reflect product XX.X% operating quarter to this year. of environment and of up flat commercial in quarter QX net nicely responsiveness compared the which last third team’s these sales our changing to our changes as are the third rapidly from we're
business. the model greater made has third centric During completed our to more agile the and over quarter, given hub commercial model. us control we conversion the This us
developments. while Importantly, of it the maximize has enabled factors of negative to other benefit us effects dynamics to minimizing to external the quickly changing trends, market adapt and positive
the of sales model, identified third September, the issue evidence products. demonstrates of change as net and able One our metrics step this assess each minimize shifted our of our in the quickly and efforts adjust new process. which of this can on in most our per the that other Further away prescription, the in increased model acute effectiveness only for the we're telling miss SPRIX didn't to across the it business going average in interest the sales of not We in beyond hub formulary a we essentially to a as seamlessly SPRIX. resources be of taken seen which pain. to approach We believe in of forward. alternative pivot by patients, impacted the the and products. that able and and action PBM quarter is labeled decision opioid disruption We this Because to large takes negatively initial treatment best the PBM of were decidedly
healthcare, most the is severity the the that affecting of crucial While not urgent significant COVID-XX overlook opioid we it is clearly nation's matter crisis.
from to are come our we alternatives patient’s We which opioid effectively back choice, this have taking reverse. that in are decision viable in actions, opposition our will is epidemic everything power the do the which therapeutic direct to to concerned PBM efforts industry's and
each highlighted profitability adjusting execution, prudent financial commercial needed We these to in continued of committed report I cash Assertio's QX. broader commercial last growth. most driving growth pleased As support on business strategy we've focused on quarter, three progress approach our And am development. and on our I initiatives remain based effectively is flow fundamental elements; that profitable to sustainable and as controls to made
by commercial quarter a the afforded of model. and elective to our compared of quarter to in quarter face from testament organization was with pro procedures maneuverability volumes challenges to third transition believe according roughly IQVIA, XXXX. is total down surgeries continue our third While We revenue essentially to the to our XX% this us the still and patient dedication hub forma for revenues flat
focus the drove third QX year. I'm coupled and we Xnd efforts weeks also were which year prior, over of we team’s over particularly excited quarter believe have by growth I grow saw move over forward. and the which still compared prescriptions ended to grow. will While XX% that over as commercial increase growth quarter impacted XX.X%. grew Zipsor Indocin, to sales our XX% we able with by this Indocin business believe support execution the discussed, sales period we the two and the challenging in week XX.X% total continued SPRIX PBM environment, to Despite last room we These was meaningfully of last QX October XX action for XX
track on believe controls, per that to Looking we've initial we take our savings identified more focus the since to expenses the expenses realize importantly, synergy the the additional originally identified. managing of million the financial targets significantly quarter could already operating our to longer on million and forecasted we realize. and full these in of forma benefit profitability. on continue laser Zyla benefit beyond term Total a perhaps year $XX optimizing down additional we were at the with completion savings synergies compared third XXXX. of path We the And $XX FX business have operating the merger pro are track beyond we're to
$XX our The we controls, in third of addition strategy overall outstanding the quarter. In position. expense business our million our the of balance We plan financial growth to sheet, to strengthen debt to prudent our final steps stabilizing development. continue prepaid is taking strategic element through
flows at certain quarter this finding in cash us demonstrates third may but we were was that goal value proud expenses which would and We more focus on significantly potential diligence. was some and finding pursue have the profitability committed right our compelling and a us during incurred our diligence down the transaction a this opportunities a well [Indiscernible] deal of the to importantly, transaction our necessary related shareholders. year-over-year, deep development positive to the as team's we making did party I discipline remain value drive identified for Assertio. discussions that enable as will investments issues didn't to significant with deals create for to believe help to business While Assertio that negotiations. OpEx to us am This we have process It been materialize. achieve
to involving meeting BD transactions of next remain committed year. complementary the seek one continue or actively opportunities We and over our objective two products to
the but are actively a We taking process. to are opportunities pursuing disciplined approach BD
focused the on our deal right for that our making will portfolio, commercial are shareholders. and incremental strengthen enhance capabilities our value drive team’s We
update turn the to the on to like I Dan third of to in results for brief outlook our greater over detail, remainder discuss call provide I'd the XXXX. Before a quarter
As a continues our of uncertainty. significant to COVID, near term result industry face
strength and volume. by as of as growth seen growth weeks Zipsor, were well in results Our product continued several first third and the relatively new four, Indocin prescription in net continued quarter biggest strong X% including through quarter our we starts have Cambia, for
in that months believe this XXXX. we challenges the trend revenues we will the of XXXX us pro X% forma for year compared cumulative to While year revenues nine led full effect of decline first approximately full continue, through of have the expect the to year face
commercial new than this, to team spite We we is of of EBITDA model, are our In SPRIX. and guidance the hub in This time. products unable the believe at other transition profitable this future and proven execution manage this acquiring relates a margin our key encouraging of the growth QX commercial result growth, the reaffirm as of necessary the future to our We doing further impact period growth strategy to business it of health potential stabilizes. our the from continuing new as is while realization COVID we focus through on what are believe to products. our to
positioned profitability. be for will growth We and
for performance will quarter. the Now our review Dan third financial
